A Study to Determine Pharmacokinetics of Children Receiving Modigraf (Tacrolimus Granules) Following Solid Organ Transplantation

Inclusion Criteria: * The subject is the recipient of a solid organ (liver, kidney or heart) transplant. Multiorgan transplants are acceptable as long as one of the organs transplanted is liver, kidney or heart Exclusion Criteria: * The subject has previously received another organ transplant (including liver, kidney or heart re-transplantation) * Subject has a high immunological risk, defined as a Panel Reactive Antibody (PRA) score \>50% in the previous 6 months (only applicable for renal transplant recipients) * Cold ischemia time of the donor kidney greater than 30 hours (only applicable for renal transplant recipients) * Subject receives an AB0 incompatible donor organ * Subject has significant renal impairment, defined as having serum creatinine ≥230 μmol/l (≥2.6 mg/dl) pre-transplantation (not applicable for renal transplant recipients) * Subject has significant liver disease, defined as having elevated Alanine Aminotransferase (ALT) and/or Asparate Aminotransferase (AST) and/or Total Bilirubin levels 3 times the upper value of the normal range during the 28 days prior to transplantation (not applicable for liver transplant recipients) * Subject with pulmonary vascular resistance greater than 4 Wood units which is unresponsive to treatment * Subjects with malignancies or a history of malignancy within the last 5 years * Subject has a significant, uncontrolled systemic infection and/or severe diarrhea, vomiting, active upper gastrointestinal disorder that may affect the absorption of tacrolimus or has an active peptic ulcer * Subject requires systemic immunosuppressive medication for any indication other than transplantation * Recipient or donor known to be HIV, HCV or HBV positive * Known allergy or intolerance to steroids, macrolide antibiotics, basiliximab or tacrolimus * Subject is currently participating in another clinical trial and/or has been taking an investigational drug in the 3 months prior to transplantation * Subject is unlikely to comply with the visits scheduled in the protocol * Subjects taking or requiring to be treated with medication or substances prohibited by this protocol